Welcome to our dedicated page for Compass Pathways Plc SEC filings (Ticker: CMPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Compass Pathways� latest disclosures isn’t easy. Each 10-K weaves FDA feedback, psilocybin chemistry, and multi-year cash-runway tables into dense blocks of text. Add surprise 8-K releases about trial milestones and Form 4 trades by scientific founders, and you’re soon juggling dozens of documents. Investors searching for “Compass Pathways SEC filings explained simply� or “Compass Pathways 8-K material events explained� want answers, not page counts.
Stock Titan delivers that clarity. Our AI ingests every Compass Pathways quarterly earnings report 10-Q filing within minutes of hitting EDGAR, then highlights R&D spend trends and patient-response data. You receive real-time alerts when Compass Pathways Form 4 insider transactions real-time appear, and our dashboards link each trade to clinical news. Need a quick brief? Choose any filing type below—our summaries turn biotech jargon into plain English so you can focus on decisions, not deciphering.
- Compass Pathways annual report 10-K simplified
- Compass Pathways insider trading Form 4 transactions
- Compass Pathways proxy statement executive compensation
- Compass Pathways earnings report filing analysis
With those insights, professionals track how COMP360 trial costs flow through the income statement, compare cash burn to milestone payments, and monitor Compass Pathways executive stock transactions Form 4 for signals of confidence. Whether you’re modeling dilution risk or understanding Compass Pathways SEC documents with AI, our platform keeps every disclosure organized, searchable, and actionable.
Compass Pathways plc (CMPS) filed an 8-K to disclose that its pivotal Phase 3 COMP005 study met its primary endpoint in treatment-resistant depression (TRD). In the randomized, double-blind trial (n = 258 across 32 U.S. sites), a single 25 mg dose of COMP360 psilocybin produced a statistically significant reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) scores versus placebo at week 6 (mean difference �3.6 points; 95% CI [�5.7, �1.5]; p < 0.001). Safety, reviewed by the independent DSMB on 19 June 2025, was consistent with prior studies and showed no new or unexpected adverse signals, including suicidality.
COMP005 has three parts, with Parts A (through week 6) now unblinded, Part B blinded to week 26, and Part C open-label through week 52. The parallel COMP006 trial (planned n = 568) compares two fixed dosing regimens and remains blinded. The company expects to release 26-week data for COMP005 after all COMP006 participants complete Part A; 26-week COMP006 data are targeted for H2 2026.
The positive read-out strengthens CMPS’s regulatory pathway, but the FDA has not yet reviewed the data, full safety assessments are pending, and additional capital will likely be required to complete development and pursue commercialization. Forward-looking statements highlight clinical, regulatory, and financing risks.
FAQ
What is the current stock price of Compass Pathways Plc (CMPS)?
What is the market cap of Compass Pathways Plc (CMPS)?
What does Compass Pathways Plc do?
What is COMP360?
What makes Compass Pathways unique in the mental health industry?
What is treatment-resistant depression (TRD)?
What regulatory designations has COMP360 received?
How does Compass Pathways collaborate with other organizations?
What clinical trials is Compass Pathways conducting?
Where is Compass Pathways headquartered?
What challenges does Compass Pathways face?
What is Compass Pathways' long-term vision?
